Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Phase Ib/II trial with ADH-1 initiated in advanced cancer patients
June 17th, 2005
Adherex Technologies, Inc., (ADH, AHX) has initiated a phase Ib/II clinical trial of ADH-1 (Exherin) at the M.D. Anderson Cancer Center in Houston, Texas, in advanced cancer patients who express the tumor molecular target N-cadherin. This study will explore a "daily x 5" dosing schedule with daily dosing Monday through Friday every 3 weeks. The study, the company's second phase Ib/II trial with ADH-1, is designed to define the maximum tolerated dose and to evaluate the safety, tolerability and antitumor activity of repeated and ascending doses of ADH-1. The effect of the drug on tumor vasculature will be assessed in some patients through dynamic...
Source: Drug Week (2005-06-17)
|
